Date: 2014-12-03
Type of information: Collaboration agreement
Compound: NV-01
Company: Virbac (France) Nexvet (UK)
Therapeutic area: Veterinary medicine
Type agreement: collaboration distribution
Action mechanism: monoclonal antibody. NV-01 is an anti-nerve growth factor monoclonal antibody for the control of pain associated with osteoarthritis in dogs, which has recently commenced its pivotal safety and effectiveness study.
Disease: pain associated with osteoarthritis in dogs
Details: * On December 3, 2014, veterinary biologic therapy developer Nexvet Biopharma announced the signing of a ten year collaboration and distribution agreement with Virbac, one of the largest animal health dedicated companies in the world. The aim of this agreement is for Virbac to provide input to Nexvet’s development of new monoclonal antibody-based veterinary medicines and to market these medicines, if approved by regulators, outside the USA and Canada. The first medicine under the agreement between Virbac and Nexvet, NV-01, targets the control of pain associated with osteoarthritis in dogs. Under the terms of the agreement, Virbac will distribute NV-01 for the control of pain associated with osteoarthritis in dogs, in territories outside the U.S. and Canada. Nexvet will have responsibility for development, manufacturing and supply of NV-01 while Virbac will provide clinical and regulatory advice and have responsibility for distribution, marketing and sales of NV-01 in Europe and other non-U.S. or Canadian territories. Nexvet will retain sole distribution rights to NV-01 in the U.S. and Canada. A Joint Steering Committee will be established to optimize clinical development, regulatory submissions, medical education and marketing strategies. Virbac will have the right to negotiate access to future Nexvet products on a product-by-product basis for development, distribution, marketing and sales. This is subject to separately agreedupon financial terms.
Financial terms: The parties have agreed to share profits from Virbac’s sales of NV-01 equally. In addition, Virbac will pay Nexvet milestone payments upon NV-01’s first marketing authorization and its first commercialization in a major European country.
Latest news:
